Last reviewed · How we verify
Olopatadine 0.1% Rescue Treatment
Olopatadine 0.1% Rescue Treatment is a H1-receptor antagonist / mast cell stabilizer Small molecule drug developed by ALK-Abelló A/S. It is currently in Phase 3 development for Allergic conjunctivitis (rescue/acute treatment). Also known as: Pantanol.
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the eye.
Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the eye. Used for Allergic conjunctivitis (rescue/acute treatment).
At a glance
| Generic name | Olopatadine 0.1% Rescue Treatment |
|---|---|
| Also known as | Pantanol |
| Sponsor | ALK-Abelló A/S |
| Drug class | H1-receptor antagonist / mast cell stabilizer |
| Target | H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Olopatadine works through dual action: it competitively antagonizes H1 receptors on ocular tissues to block histamine-induced symptoms, and simultaneously stabilizes mast cells to prevent degranulation and release of inflammatory mediators. This combination provides both rapid symptom relief and sustained anti-allergic effects for ocular allergy management.
Approved indications
- Allergic conjunctivitis (rescue/acute treatment)
Common side effects
- Ocular irritation
- Headache
- Conjunctival hyperemia
- Taste perversion
Key clinical trials
- Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) (PHASE3)
- Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Olopatadine 0.1% Rescue Treatment CI brief — competitive landscape report
- Olopatadine 0.1% Rescue Treatment updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI
Frequently asked questions about Olopatadine 0.1% Rescue Treatment
What is Olopatadine 0.1% Rescue Treatment?
How does Olopatadine 0.1% Rescue Treatment work?
What is Olopatadine 0.1% Rescue Treatment used for?
Who makes Olopatadine 0.1% Rescue Treatment?
Is Olopatadine 0.1% Rescue Treatment also known as anything else?
What drug class is Olopatadine 0.1% Rescue Treatment in?
What development phase is Olopatadine 0.1% Rescue Treatment in?
What are the side effects of Olopatadine 0.1% Rescue Treatment?
What does Olopatadine 0.1% Rescue Treatment target?
Related
- Drug class: All H1-receptor antagonist / mast cell stabilizer drugs
- Target: All drugs targeting H1 receptor
- Manufacturer: ALK-Abelló A/S — full pipeline
- Therapeutic area: All drugs in Ophthalmology / Allergy
- Indication: Drugs for Allergic conjunctivitis (rescue/acute treatment)
- Also known as: Pantanol
- Compare: Olopatadine 0.1% Rescue Treatment vs similar drugs
- Pricing: Olopatadine 0.1% Rescue Treatment cost, discount & access